In today’s episode, we spoke with Nisha Joseph, MD, and Hans Lee, MD, about the FDA's accelerated approval of linvoseltamab-gcpt (Lynozyfic) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Joseph is an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta, Georgia. Lee is the director of Myeloma Research at the Sarah Cannon Research Institute in Nashville, Tennessee. 

In our conversation, Drs Lee and Joseph discussed the significance of this approval, key data from the pivotal phase 1/2 LINKER-MM1 trial (NCT03761108), and where linvoseltamab fits into the relapsed/refractory myeloma treatment paradigm alongside other approved agents. 

In our conversation, Dr Akhave discussed the addition of toripalimab (Loqtorzi), a PD-1 inhibitor, to the NCCN Guidelines following its launch in the United States. Supported by data from the phase 3 JUPITER-02 trial (NCT03581786), toripalimab is now incorporated into frontline therapy for patients with recurrent metastatic or de novo metastatic Epstein–Barr virus (EBV)–positive NPC, in combination with gemcitabine and cisplatin. He explained how this regimen has produced substantial improvements in progression-free survival (PFS), nearly tripling median PFS compared with chemotherapy alone, while maintaining a manageable safety profile.

In this episode, Raval welcomed David A. Frank, MD, PhD, FACP, who is director of the Division of Hematology and a professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. He also serves as director of the Winship Innovation Initiative and as an advisor to the Morningside Center for Innovative and Affordable Medicine within the Woodruff Health Sciences Center.

In our conversation, Dr García-Carbonero discussed a subgroup analysis from the phase 3 FRESCO-2 trial (NCT04322539), which evaluated fruquintinib (Fruzaqla) in previously treated metastatic CRC (mCRC). She reviewed efficacy outcomes by metastatic site, including liver-only, lung-only, bone, and peritoneal disease. Fruquintinib demonstrated improvements in overall survival and progression-free survival across all subgroups, underscoring its feasibility in later-line settings for patients with mCRC. She also addressed prognostic differences between metastatic sites, noting that all patient groups derived benefit from treatment. Dr García-Carbonero also shared findings from PROMETCO, the first international, prospective, real-world study in mCRC, which is examining real-world outcomes for this patient population. 

In this episode, OncLive On Air® partnered with Two Onc Docs, Tawagi and Armstrong reviewed key principles in the diagnosis and management of uterine and endometrial cancers, incorporating updates in surgical approaches, adjuvant therapy selection, molecular testing, and the management of rare uterine sarcomas. The discussion outlined the epidemiology, risk factors, clinical presentation, diagnostic evaluation, staging, histologic classification, and treatment algorithms relevant to board preparation and clinical practice.

In our exclusive interview, Dr Blanco discussed the significance of this regulatory milestone for a population that has historically lacked effective medical options. He reviewed the pivotal phase 2b ReNeu clinial trial (NCT03962543)that supported this decision, which enrolled both adult and pediatric patients with nonresectable PNs and evaluated clinical and radiologic response rates. Dr Blanco detailed the study’s findings, including overall response rates of 41% and 52% in the adult and pediatric populations, respectively; meaningful reductions in tumor volume; improvements in patient-reported pain and quality of life; and the favorable safety profile characterized primarily by dermatologic and gastrointestinal adverse effects.

In our exclusive interview, Dr Élez discussed recent data comparing nivolumab (Opdivo) monotherapy with nivolumab plus ipilimumab (Yervoy) across multiple lines of therapy in patients with MSI-H mCRC. She detailed efficacy and quality‑of‑life outcomes, noting that the combination appeared to offer enhanced clinical benefit without a negative effect on tolerability. Dr Élez also highlighted the importance of tailoring immunotherapy strategies based on patient characteristics and treatment goals and reflected on the nuances of sequencing single‑agent vs combination checkpoint blockade.

In today’s OncClub episode, we had the pleasure of speaking with Shailee S. Shah, MD, about a retrospective study she and colleagues conducted to understand the effect of immune checkpoint inhibitors on patients with cancer and pre-existing neurologic autoimmune diseases, including multiple sclerosis, myasthenia gravis, Guillain-Barre syndrome, and Parkinson's disease. Dr Shah is a clinical assistant professor of neurology (MS/neuroimmunology) at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. 

In our exclusive interview, Dr Shah discussed the design of this study, key findings, and how these results emphasize the need for multidisciplinary care and risk stratification for more effective and comprehensive patient care. 

Check out the full OncClub subseries to see additional findings and insights from this research!

In today’s episode, we had the pleasure of speaking with Martin F. Dietrich, MD, PhD, about updates and best practices for HER2 and MET immunohistochemistry (IHC) testing for patients with non–small cell lung cancer (NSCLC). Dr Dietrich is a medical oncologist at Cancer Care Centers of Brevard in Rockledge, Florida; as well as an assistant professor of internal medicine at the University of Central Florida in Orlando. 

In our exclusive interview, Dr Dietrich discussed the rationale for testing for these mutations in patients with NSCLC, standard practices for implementing these tests in the clinic, and when testing may be appropriate at disease progression. 

In today’s episode, we had the pleasure of speaking with Connie Lai, MD, a medical oncology resident at Queen Elizabeth Hospital in Hong Kong, about a retrospective, dual-center study examining post-induction treatment strategies in metastatic colorectal cancer (mCRC).